Chiral Technologies, Inc. (CTI) is the market leader in the area of enantioselective chromatography. Together with Daicel Corporation, we support all stages of the single-enantiomer drug development process from preclinical studies to commercial drug development. We offer a full range of chiral HPLC and SFC chromatography columns for analytical, semi-preparative and preparative separations. To accelerate drug development efforts, we provide the enantioselective resolution of quantities ranging from 200 milligrams to 200 kilograms of chiral compounds, under cGMP if required. We also provide process development and pilot studies for the manufacture of chiral intermediates of approved drugs.